Home > Boards > US Listed > Biotechs > Portola Phramaceuticals (PTLA)

PTLA will target a large number of hospitals

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
H2R Member Profile
 
Followed By 13
Posts 1,422
Boards Moderated 0
Alias Born 07/17/14
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 5:43:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 5:37:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 5:34:13 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 5:27:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 5:20:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 5:16:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/14/2019 4:49:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/5/2019 5:07:23 PM
Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences GlobeNewswire Inc. - 5/28/2019 4:30:00 PM
Portola Pharmaceuticals Announces New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® i... GlobeNewswire Inc. - 5/22/2019 10:45:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/8/2019 8:38:16 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/8/2019 8:07:58 AM
Portola Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 5/8/2019 8:01:00 AM
European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals’ Ondexxya™ (andexanet alfa), t... GlobeNewswire Inc. - 4/26/2019 2:00:47 PM
European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals’ Ondexxya™ (andexanet alfa), t... GlobeNewswire Inc. - 4/26/2019 2:00:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/25/2019 11:21:27 AM
Portola Pharmaceuticals Announces Retirement of Dr. John Curnutte, Executive Vice President and Head of Research and Developm... GlobeNewswire Inc. - 4/24/2019 8:30:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/22/2019 6:03:30 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/22/2019 6:03:24 AM
Portola Pharmaceuticals to Announce First Quarter 2019 Financial Results on Wednesday, May 8, 2019 GlobeNewswire Inc. - 4/17/2019 4:15:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/16/2019 7:45:27 PM
New Research: Key Drivers of Growth for Newmont Mining, Johnson & Johnson, Portola Pharmaceuticals, MedEquities Realty Trust,... GlobeNewswire Inc. - 4/10/2019 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/8/2019 7:04:44 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/1/2019 7:28:43 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/20/2019 5:13:15 PM
H2R   Monday, 12/31/18 04:00:40 PM
Re: None
Post # of 178 
PTLA will target a large number of hospitals

Now that the PAS is approved, the CC comments can be taken more seriously.

Quote:
So we expect that to continue next year as we target more accounts. So going into the second part of your question, in terms of the Gen 2 rollout, we're - we have multiple tiers. And we've I think discussed this a little bit previously. The tier 1 or our first set of targets are about 600 U.S. hospitals are Level I or Level II trauma centers or have Comprehensive Stroke designation. So those are the biggest institutions across the country. The next tier of about 900 additional accounts, additional hospitals were the Advanced Stroke Center designation.

So those are all pretty important accounts for us. And then finally, from what we've seen in the Early Supply Program, we also want to be able to stock affiliates of these accounts too, because oftentimes patients might present to an affiliate account. That's where we want the drug to get started, if they're showing up there. And then they're transferred to the larger account. So we'll be going on next year to target as many as we can.


Scott Garland, CEO

https://seekingalpha.com/article/4219652-portola-pharmaceuticals-ptla-ceo-scott-garland-q3-2018-results-earnings-call-transcript?part=single

This is to pair up with today's PR:
Quote:
Full Commercial Launch to Begin January 2019


http://investors.portola.com/phoenix.zhtml?c=198136&p=irol-newsArticle&ID=2381753

I do expect a very good stock performance in 2019



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist